Table 4.
Questionnaires and laboratory results compared severe and mild patients with COVID-19
| Severe (N = 9) | Mild (N = 82) | P value | |
|---|---|---|---|
| Age (years) | 66 (54–80) | 49 (35.3–56) | 0.000167 |
| MuLBSTA | 13 (11–13) | 5 (1.5–7) | <0.0001 |
| Blood routine | |||
| Leucocytes | 5.23 (4.74–6.8) | 4.97 (4.02–5.65) | 0.01078 |
| Neutrophils | 3.32 (3–5.82) | 2.8 (2.18–3.49) | 0.00041 |
| Lymphocytes | 0.9 (0.7–1.3) | 1.4 (1.05–1.75) | 0.02702 |
| Mononuclear leucocyte | 0.35 (0.3–0.7) | 0.4 (0.3–0.59) | 0.18341 |
| Eosinophils | 0.01 (0–0.01) | 0.02 (0.01–0.06) | 0.14742 |
| Basophil | 0 (0–0.01) | 0.01 (0.01–0.02) | 0.01869 |
| Red blood cell | 4.26 (3.8–4.82) | 4.49 (4.17–4.81) | 0.46518 |
| Haemoglobin | 130 (118–142) | 135 (126–147) | 0.27599 |
| Platelets | 152 (127–208) | 198 (144–248) | 0.51192 |
| Thrombocytocrit | 0.16 (0.13–0.21) | 0.21 (0.16–0.25) | 0.32815 |
| Fibrinogen | 3.8 (3.71–4.15) | 3.36 (2.64–4.08) | 0.18738 |
| D-dimer | 450 (160–485) | 300 (106–400) | 0.59192 |
| Blood chemistry | |||
| Alanine aminotransferase | 19.9 (14–26) | 18 (13–29) | 0.75424 |
| Aspartate aminotransferase | 27 (23.75–27) | 21 (17–29) | 0.89006 |
| Albumin | 38.55 (36.33–39.25) | 40.2 (38–42.4) | 0.13321 |
| Urea | 5.19 (4.66–6.14) | 3.83 (3.25–4.4) | <0.0001 |
| Serum creatinine | 81.5 (70.75–90.5) | 66 (57–76) | 0.03718 |
| K± | 3.82 (3.76–3.89) | 4.09 (3.72–4.27) | 0.35867 |
| Na± | 137.85 (135.3–139.38) | 139.6 (137.6–142) | 0.02714 |
| Cl− | 101.4 (99.28–104.5) | 103.4 (101.28–105.23) | 0.31589 |
| Ca2± | 2.01 (1.86–2.01) | 2.17 (2.07–2.25) | 0.00566 |
| Infection-related biomarkers | |||
| C-reactive protein | 30.63 (12.5–103.4) | 5.98 (1.4–11.3) | <0.0001 |
| Procalcitonin | 0 (0) | 0.03 (0–0.04) | 0.00358 |
Values are expressed as medians (interquartile ranges) or n (%), where N is the number of patients with available data. P values comparing severe and mild pneumonia patients are from χ2, Fisher’s exact test or Mann–Whitney U-test. COVID-19 = 2019 novel coronavirus diseases.